Marksans
Live Price
Recent news and updates for MARKSANS will appear here soon.
"Balanced market signals for MARKSANS. The stock is currently consolidating with neutral technical indicators and fundamental alignment between current healthcare growth rates and prevailing valuation metrics."
Verified by Stockmo Intelligence Grid
Citing cross-referenced internal documents and market technicals
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
As of the latest market session, Marksans (MARKSANS) is trading at ₹310, representing a move of 1.24% from the previous close.
Marksans is listed and traded under the ticker symbol MARKSANS on the National Stock Exchange of India (NSE) and Bombay Stock Exchange (BSE).
Today, Marksans's stock price moved by 1.24%. Long-term growth trends depend on company financials, technical moving averages, and sector momentum in the Healthcare industry.
Our proprietary AI Momentum engine calculates a 35% bullish probability for MARKSANS stock over the next 3-5 days. View the live interactive chart on Stockmo to see dynamic technical forecasting.
Over the past 52 weeks, Marksans shares reached a high of ₹350.95 and hit a low of ₹155.
MARKSANS exhibits standard volatility for a Healthcare stock, with an average daily trading volume of 5,40,743 shares. Detailed technical beta indicators are available on the Stockmo charting engine.
Marksans has a market capitalization of ₹14048.08 Cr, designating its size class inside the Healthcare sector.
Marksans has a current dividend yield of 29.00%. Companies may adjust payout ratios depending on quarterly earnings growth and reinvestment opportunities.
Marksans's trailing Price-to-Earnings (P/E) ratio is 27.17. This indicates how much investors are willing to pay for every rupee of the company's annual net earnings.
You can purchase Marksans (MARKSANS) shares through any SEBI-registered stockbroker (such as Kite/Zerodha, Groww, or Angel One) by funding your trading account and executing a buy order on the NSE or BSE.
Marksans's financial health, solvency, growth, and quality metrics are tracked using our proprietary Multibagger V2 score. You can explore MARKSANS's detailed 5-tier financial scorecard and compare it with market competitors on the Stockmo Multibagger Screener page.
Institutional order blocks and pristine support/resistance triggers for MARKSANS are monitored in real-time. View live technical entry levels, stop loss bounds, and target prices on our interactive Supply & Demand Trading Engine or scan entire market segments using the Basket Scanner.
Marksans operates inside the Healthcare sector. You can analyze sector-wide trends, relative strengths, and locate top emerging leaders in this space using our Sector Analysis Hub.